ACHN News and Press, Achison Inc Cl A From 08/29/19

BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President a...

Overview/Thesis: Over this past week, Amgen ( AMGN ) was rumored to be interested in buying out Alexion ( ALXN ), the biotech leader in developing treatments for diseases of the complement system, for over $40 billion. Ignored in the hubbub over that rumor was the fact that there simultane...

You only have to do very few things right in your life so long as you don't do too many things wrong. - Warren Buffett Though successful innovation entails mega-profits, the field is fraught with risks. Therefore, a bioscience theme that I like is when a company genuinely admits failure an...

– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – – ACH-5228’s near complete and sustained inhibition of the alter...

Achillion Pharmaceuticals ( ACHN ) had achieved a massive surge in stock price recently. It all started when it had reported positive data from a phase 1 study using its drug ACH-5228. This data was early, but investors were optimistic based on the initial findings of the impressive sustai...

Shares of Achillion Pharmaceuticals ( ACHN ) have experienced an impressive 95% increase over the past five days due to encouraging Phase 1 data reported for complement factor D inhibitor candidate ACH-5228. Since the beginning of 2019, the stock has risen by over 190%. After such a high deg...

Gainers:  Smith Micro Software (NASDAQ: SMSI ) +42% . Harvard Bioscience (NASDAQ: HBIO ) +38% . Solid Biosciences (NASDAQ: SLDB ) +31% . GlobalSCAPE (NYSEMKT: GSB ) +29% . LiveXLive Media (NASDAQ: LIVX ) +27% . eHealth (NASDAQ: EHTH ) +26% . Achillion Pharmaceuticals (NASDAQ: AC...

Achillion Pharmaceuticals ( ACHN +24.4% ) is up on a 6x surge in volume. Shares have rallied  102%  this week after it announced encouraging Phase 1 data on complement factor D inhibitor candidate ACH-5228 . More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks ne...

ACHN stock has been on a roll for two days straight after Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced positive updates from the Phase 1 study of its product ACH-5228, an experimental oral factor D inhibitor. ACHN Stock Goes Wild The announcement was made on Monday, and soon ...

Gainers : Therapix Biosciences (NASDAQ: TRPX ) +45% . Chiasma (NASDAQ: CHMA ) +31% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +24% . Hoth Therapeutics (NASDAQ: HOTH ) +20% . Torchlight Energy Resources (NASDAQ: TRCH ) +17% . Realogy Holdings (NYSE: RLGY ) +16% . ClearSign Combustion...